NICE (UK) recommends Crysvita (burosumab) to treat X-linked hypophosphatemia in children – Kyowa Kirin
Burosumab is NICE recommended, within its marketing authorisation, for treating X- linked hypophosphatemia (XLH) with radiographic evidence of bone disease in babies, children and young people 1 to… read more.
